Inventor · disambiguated record
Meghan Casey
Also filed as: CASEY MEGHAN · CASEY MEGHAN E
17 granted patents·11 pending applications·76 citations·filing 2016–2025
94Inventor score
Top patents by PatentIndex Score
28 records- 0198US12012445B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2023·Granted Jun 18, 2024·4 cites·30 claims
- 0298US11958894B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2023·Granted Apr 16, 2024·5 cites·30 claims
- 0398US11732025B2Anti-VEGF protein compositions and methods for producing the sameREGENERAN PHARMACEUTICALS INC·Filed 2022·Granted Aug 22, 2023·11 cites·30 claims
- 0498US11548932B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2022·Granted Jan 10, 2023·8 cites·30 claims
- 0597US12012444B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2023·Granted Jun 18, 2024·2 cites·19 claims
- 0697US11753459B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2022·Granted Sep 12, 2023·5 cites·30 claims
- 0797US11535663B2Methods for producing aflibercept in chemically defined media having reduced aflibercept variantsREGENERON PHARMA·Filed 2021·Granted Dec 27, 2022·6 cites·10 claims
- 0897US11472861B2Methods for producing aflibercept in chemically defined media having reduced aflibercept variantsREGENERON PHARMA·Filed 2021·Granted Oct 18, 2022·5 cites·26 claims
- 0997US11104715B2Methods for producing aflibercept in chemically defined media having reduced aflibercept variantsREGENERON PHARMA·Filed 2020·Granted Aug 31, 2021·5 cites·16 claims
- 1096US10927342B2Taurine supplemented cell culture medium and methods of useREGENERON PHARMA·Filed 2020·Granted Feb 23, 2021·23 cites·28 claims
- 1194US12338274B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2024·Granted Jun 24, 2025·0 cites·30 claims
- 1294US12319728B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2024·Granted Jun 3, 2025·0 cites·30 claims
- 1394US11505594B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2022·Granted Nov 22, 2022·1 cites·27 claims
- 1493US2024294606A1Anti-vegf protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1590US12359166B2Taurine supplemented cell culture medium and methods of useREGENERON PHARMA·Filed 2024·Granted Jul 15, 2025·0 cites·29 claims
- 1690US12359165B2Taurine supplemented cell culture medium and methods of useREGENERON PHARMA·Filed 2024·Granted Jul 15, 2025·0 cites·30 claims
- 1788US12221619B2Taurine supplemented cell culture medium and methods of useREGENERON PHARMA·Filed 2023·Granted Feb 11, 2025·0 cites·30 claims
- 1888US2025340832A1Taurine supplemented cell culture medium and methods of useREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 1986US2025289868A1Anti-vegf protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 2085US2025327023A1Taurine supplemented cell culture medium and methods of useREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 2182US2023348532A1Manufacturing process for high titer antibodyREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2282US2023331776A1Manufacturing process for high titer antibodyREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2382US2023332084A1Bioreactor for antibody productionREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2482US2023287043A1Cell culture methods for antibody productionREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2582US2023332201A1Cell culture methods for antibody productionREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2682US2024010737A1Manufacturing process for high titer antibodyREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2780US11312936B2Taurine supplemented cell culture medium and methods of useREGENERON PHARMA·Filed 2016·Granted Apr 26, 2022·1 cites·29 claims
- 2854US2023063116A1Vegf mini-traps and method of use thereofREGENERON PHARMA·Filed 2020·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →